Pharmacokinetics of monoclonal antibodies

Josiah T. Ryman, Bernd Meibohm

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.

Original languageEnglish (US)
Pages (from-to)576-588
Number of pages13
JournalCPT: Pharmacometrics and Systems Pharmacology
Volume6
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Monoclonal antibodies
Pharmacokinetics
Monoclonal Antibody
Monoclonal Antibodies
Drugs
United States Food and Drug Administration
Backbone
Therapy
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Modeling and Simulation
  • Pharmacology (medical)

Cite this

Pharmacokinetics of monoclonal antibodies. / Ryman, Josiah T.; Meibohm, Bernd.

In: CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, No. 9, 01.09.2017, p. 576-588.

Research output: Contribution to journalArticle

@article{93c457f6c8c64809ab131d8cb8c4b52a,
title = "Pharmacokinetics of monoclonal antibodies",
abstract = "Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.",
author = "Ryman, {Josiah T.} and Bernd Meibohm",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/psp4.12224",
language = "English (US)",
volume = "6",
pages = "576--588",
journal = "CPT: Pharmacometrics and Systems Pharmacology",
issn = "2163-8306",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Pharmacokinetics of monoclonal antibodies

AU - Ryman, Josiah T.

AU - Meibohm, Bernd

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.

AB - Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for mAbs, and will highlight product-specific and patient-specific factors that modulate their pharmacokinetic (PK) behavior and need to be considered for successful clinical therapy.

UR - http://www.scopus.com/inward/record.url?scp=85026489882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026489882&partnerID=8YFLogxK

U2 - 10.1002/psp4.12224

DO - 10.1002/psp4.12224

M3 - Article

VL - 6

SP - 576

EP - 588

JO - CPT: Pharmacometrics and Systems Pharmacology

JF - CPT: Pharmacometrics and Systems Pharmacology

SN - 2163-8306

IS - 9

ER -